Introduction
Growth hormone plays an important role in childhood growth and in several processes throughout adulthood. When the body does not produce enough growth hormone, or when certain approved conditions affect normal growth, growth hormone therapy may be part of treatment.
Sogroya is a long-acting growth hormone analog administered once weekly. It is approved for several pediatric growth-related conditions and for growth hormone deficiency in adults. For eligible patients who face challenges accessing their medication, Prescription Hope may help navigate prescription assistance and treatment costs.
What Is the Sogroya Patient Assistance Program?
While looking for Sogroya medication access, some patients may have seen something called the Sogroya Patient Assistance Program.
But what is a patient assistance program, and how can it help qualified patients get the medications they need?
Some pharmaceutical manufacturers understand that the name-brand medication they sell may place financial strain on already struggling American patients. Factors like gaps in government coverage, inadequate insurance, or loss of coverage leave patients reeling at how much money their name-brand medication costs.
These manufacturers have developed ways to help patients access the name-brand medications they need.
Prescription assistance programs, like Sogroya prescription assistance, help qualified patients get the name-brand medication at a lower cost than market value. Patients must meet certain requirements such as income thresholds, insurance coverage, and residency to qualify for these programs.
The drawback is that applications to these prescription assistance programs typically include a complex process, with extensive documentation and in-depth coordination between the pharmaceutical manufacturer and the patient’s healthcare provider. But Prescription Hope is here to help.
How Expert Advocates Help Make Sogroya More Affordable
Personalized Medication Assistance
Prescription Hope offers Sogroya medication support throughout the application process. We also provide service after a qualified patient’s application to a patient assistance program is accepted. Our team of Sogroya patient advocates provides help with needed administrative tasks, including form completion, document and signature collection, coordinating with healthcare providers and manufacturers, dispute advocacy and support, and more.
Ongoing Patient Support
Even after approval into a patient assistance program, our team is here to help with ongoing growth hormone patient support. Our team of medication access advocates will continue to assist you with continued patient assistance program access with any personalized prescription assistance needs. We continue to advocate for you through services such as refill scheduling, document updates, yearly renewals, program monitoring, and more.
Sogroya Price Comparison
vs
Estimated Retail Price*
30-Day Supply
Prescription Hope Price
Per Month, NO Matter The Retail Price
*Source: Drugs.com
Sogroya Patient Assistance Eligibility
Sogroya prescription assistance eligibility varies depending on which prescription assistance program the patient utilizes. To ensure a patient meets Sogroya assistance requirements, please check with Prescription Hope. However, all patient assistance programs keep criteria in several categories, such as:
Income: All programs set their own criteria for the patient’s income threshold.
Insurance: All programs also set their own criteria regarding insurance coverage status.
Prescription: Qualified patients must have a valid prescription for the name-brand medication they seek to apply for.
U.S. Residency: Qualified patients must also be legal American citizens.
Simple Enrollment With Expert Support
Ready to submit your Sogroya patient assistance application? Prescription Hope’s medication assistance enrollment takes 6 simple steps:
- Submit Information: Our online enrollment form takes just a few minutes to complete.
- Advocate Contact: A patient advocate will contact you in 1-2 business days after we receive your completed enrollment form.
- Document Collection: After the prequalification phase, our team will collect all necessary documents from you and your healthcare provider.
- Provider Coordination: We will also get any needed signatures from your healthcare provider.
- Program Submission: We will continue to coordinate with the manufacturer as we put all of your information together and submit your application to the patient assistance program on your behalf.
- Medication Delivery: Patients normally receive their medication 2 weeks after their application is approved.
Prescription Hope does not handle medication because they are not a pharmacy or manufacturer. Therefore, all medications ship directly to your door or doctor’s office.
Understanding Sogroya
How Sogroya Works
Sogroya contains somapacitan-beco, a long-acting human growth hormone analog. It binds to growth hormone receptors on target cells and triggers intracellular signaling and other growth hormone-related effects.
Some effects occur directly through growth hormone receptor signaling, while others are primarily mediated by increased production of insulin-like growth factor-1 (IGF-1), particularly in the liver. Its reversible albumin binding delays elimination and prolongs its duration of action, allowing once-weekly dosing.
What Conditions Does Sogroya Treat?
Sogroya is indicated for pediatric patients aged 2.5 years and older with growth failure caused by inadequate secretion of endogenous growth hormone, short stature in children born small for gestational age who have not experienced catch-up growth by age 2, growth failure associated with Noonan syndrome, and idiopathic short stature.
In adults, Sogroya is indicated as replacement of endogenous growth hormone in adults with growth hormone deficiency. It is not indicated for growth failure secondary to genetically confirmed Prader-Willi syndrome.
Benefits of Treatment
Sogroya provides growth hormone replacement once weekly rather than requiring daily growth hormone injections. In pediatric patients with growth hormone deficiency, once-weekly Sogroya increased annualized height velocity over 52 weeks and produced a mean height-standard-deviation-score increase in the pivotal study. In adults with growth hormone deficiency, This medication reduced truncal fat percentage compared with placebo and normalized mean IGF-1 standard deviation scores in the pivotal trial.
Important Safety Information and Side Effects
Increased Mortality in Acute Critical Illness
Growth hormone treatment should not be used in patients with acute critical illness associated with open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure.
Severe Hypersensitivity
Serious allergic reactions, including anaphylaxis and angioedema, can occur with this medication.
Increased Risk of Neoplasms
Growth hormone may increase the risk of tumor growth or recurrence in certain patients. Childhood cancer survivors, particularly those previously treated with radiation to the brain or head, require appropriate monitoring.
Glucose Intolerance and Diabetes
Sogroya can decrease insulin sensitivity and may cause or worsen hyperglycemia or diabetes.
Intracranial Hypertension
Increased pressure within the skull can occur. Fundoscopic examinations should be performed before treatment and periodically thereafter.
Fluid Retention
Edema and other fluid-retention effects, including joint or muscle symptoms and nerve-compression symptoms, can occur.
Hypoadrenalism and Hypothyroidism
This medication can reduce serum cortisol levels and may require adjustment of glucocorticoid replacement therapy. It may also cause or worsen hypothyroidism.
Slipped Capital Femoral Epiphysis and Scoliosis
Children receiving growth hormone who develop a limp or persistent hip or knee pain should be evaluated for slipped capital femoral epiphysis. Preexisting scoliosis may progress during periods of rapid growth.
Pancreatitis
Persistent or severe abdominal pain should be evaluated for pancreatitis.
Injection-Site Complications
Injection sites should be rotated regularly to reduce the risk of lipohypertrophy and lipoatrophy.
Prader-Willi Syndrome
Fatalities have been reported in pediatric patients with Prader-Willi syndrome receiving growth hormone, particularly those with severe obesity, upper-airway obstruction, sleep apnea, or respiratory infection. Sogroya is not indicated for growth failure secondary to genetically confirmed Prader-Willi syndrome.
Laboratory Tests
Sogroya may increase serum inorganic phosphorus, alkaline phosphatase, and parathyroid hormone levels.
Drug Interactions
Patients receiving glucocorticoid replacement for hypoadrenalism may require increased maintenance or stress doses after starting Sogroya.
Sogroya may alter the clearance of drugs metabolized by CYP450 enzymes, so careful monitoring is recommended. Women receiving oral estrogen may require higher Sogroya doses because oral estrogen can reduce the IGF-1 response. Sogroya may also reduce insulin sensitivity and require adjustment of insulin or other antihyperglycemic medications.
Pregnancy and Breastfeeding
There are no available data specifically describing Sogroya use during pregnancy. Published studies of short-acting recombinant growth hormone have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies of somapacitan-beco did not demonstrate teratogenicity at clinically relevant exposures.
It is not known whether somapacitan-beco is present in human milk or whether it affects a breastfed infant or milk production. Somapacitan-beco-related material was detected in the milk of lactating rats.
Common Side Effects
Common adverse reactions in pediatric patients include cough, diarrhea, ear infection, headache, injection-site reaction, nasopharyngitis, pain in an extremity, fever, respiratory tract infection, and vomiting.
In adults with growth hormone deficiency, reported adverse reactions include back pain, joint pain, indigestion, sleep disorders, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, hypertension, increased creatine phosphokinase, weight gain, and anemia.
Access to Multiple Medications
Sometimes patients who are undergoing growth hormone therapy need assistance for multiple prescriptions and the medication affordability support that goes along with those name-brand medications.
Prescription Hope medication assistance is available for hundreds of brand-name medications. Every name-brand medication a patient qualifies for is available to them through Prescription Hope for the same rate of $70.00 per month, per medication.
Why Choose Prescription Hope for Sogroya Assistance?
Patient-Focused Medication Support
Since 2006, Prescription Hope has given personalized medication assistance to patients across America. We are proud to offer Sogroya prescription support through Prescription Hope.
Simplified Access to Specialty Therapies
Prescription Hope charges a simple fee of $70.00 per month, per medication. This includes no hidden fees, no long contracts, no add-ons, and no medication costs.
Ongoing Prescription Assistance
Prescription Hope’s team will advocate for you through your application process and into long-term care. Administrative tasks we assist with include refill scheduling, document updates, yearly renewals, and more.
Network Access
Our network includes hundreds of name-brand medications and their associated patient assistance programs, offering everyday Americans from big cities to rural areas affordable medication access.
If you need Sogroya and don’t know how the cost will fit into your budget, reach out to Prescription Hope to see how we can help you save money today.